Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC

Watchlist Manager
Cyclacel Pharmaceuticals Inc Logo
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Watchlist
Price: 6.365 USD -5.98% Market Closed
Market Cap: 14.3m USD

Net Margin

-64 280%
Current
Declining
by 40 613.4%
vs 3-y average of -23 666.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-64 280%
=
Net Income
$-6.4m
/
Revenue
$10k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-64 280%
=
Net Income
$-6.4m
/
Revenue
$10k

Peer Comparison

Country Company Market Cap Net
Margin
US
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
14.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 99% of companies in the United States of America
Percentile
1st
Based on 15 072 companies
1st percentile
-64 280%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Cyclacel Pharmaceuticals Inc
Glance View

Market Cap
14.3m USD
Industry
Biotechnology

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Berkeley Heights, New Jersey. The firm is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The firm is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The firm's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The firm's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.

CYCC Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-64 280%
=
Net Income
$-6.4m
/
Revenue
$10k
What is Cyclacel Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Cyclacel Pharmaceuticals Inc is -64 280%, which is below its 3-year median of -23 666.6%.

How has Net Margin changed over time?

Over the last 2 years, Cyclacel Pharmaceuticals Inc’s Net Margin has decreased from -6 478.4% to -64 280%. During this period, it reached a low of -64 280% on Jul 30, 2025 and a high of -4 450.4% on Mar 31, 2024.

Back to Top